293 related articles for article (PubMed ID: 33452716)
1. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
Hou F; Pan Z; Yang R; Zhi F; Bi Y
J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
[TBL] [Abstract][Full Text] [Related]
2. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
3. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity.
Baiden-Amissah REM; Tuyaerts S
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340438
[TBL] [Abstract][Full Text] [Related]
8. Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.
Chatelut E; Le Louedec F; Milano G
Clin Pharmacokinet; 2020 Mar; 59(3):287-296. PubMed ID: 31701469
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
Wen Y; Tang F; Tu C; Hornicek F; Duan Z; Min L
Cancer Lett; 2022 Oct; 547():215887. PubMed ID: 35995141
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
Asmar N; Ibrahim T; Rey JF
Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
[No Abstract] [Full Text] [Related]
13. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
14. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
Kim E; Ahn H; Park H
Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
17. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
Davar D; Zarour HM
Clin Cancer Res; 2022 Oct; 28(20):4370-4384. PubMed ID: 35748749
[TBL] [Abstract][Full Text] [Related]
18. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
19. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
20. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]